Abraxis Bioscience, Inc. 10-Q Quarterly Report May 2009

Company Reports Net Loss for Common Shareholders of $23 Million, or $0.57 Per Share, or Adjusted Net Loss for Common Shareholders of $6 Million, or $0.14 Per Share

•

ABRAXANE Data to be Presented at ASCO 2009 Includes Biomarker SPARC Correlative Data and Results of Combination Therapy Trials

LOS ANGELES, Calif. — May 7, 2009 — Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2009.

As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the original co-promotion agreement.

Net revenue for the first quarter of 2009 was $72.6 million compared with $82.1 million for the first quarter of 2008. Net revenue for the first quarter of 2009 included $0.8 million of recognized deferred revenue compared with $10.2 million for the same period last year. Revenue from sales of ABRAXANE for the first quarter of 2009 was $70.6 million compared with $79.9 million for the same period in 2008, which included recognition of deferred revenue of $9.1 million. Excluding the recognition of deferred revenue, total ABRAXANE revenue for the first quarter of 2009 was $70.6 million compared with $70.8 million for the comparable period in 2008.

(more)

The following information was filed by Abraxis Bioscience, Inc. on Thursday, May 7, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1409012/000119312509105547/d10q.htm

View differences made from one quarter to another to evaluate Abraxis Bioscience, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Abraxis Bioscience, Inc..

Continue

Assess how Abraxis Bioscience, Inc.'s management team is paid from their Annual Proxy

Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2009 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

CIK: 1409012
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-09-105547
Submitted to the SEC: Fri May 08 2009 5:02:21 PM EST
Accepted by the SEC: Fri May 08 2009
Period: Tuesday, March 31, 2009
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1409012/0001193125-09-105547.htm

Abraxis Bioscience, Inc. (1409012) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2009

SEC Filings

1409012 Annual Reports

1409012 Quarterly Reports

1409012 Corporate News